There are a number of significant changes from the previous version of the slide set (from 9/29/25):
• Slide 3 updates the cash balance.
• Slide 4 (pipeline chart) replaces EPS-1421 with EDP-978, the new lead compound in the KIT program.
• Slide 6 (RSV population burden) is updated with recent data on outpatient visits, hospitalization, and deaths.
• Slides 29-31 have details about EDP-978 rather than EPS-1421.
• Slides 35-40 refer to EPS-3903 specifically (the newly selected lead STAT6 compound) rather than STAT6 prototype compounds generally, and there is updated (improved) data from preclinical models.
Market Data 
Markets 
AI
